Endonovo Therapeutics Inc (ENDV)

[Craig305]

You were not wrong about the compensation.
Per the offering details just released......how can he justify such large compensation expense when absolutely "nothing" happened in 2022.
I suppose Ira received a nice bonus to join ENDV late in 2022.

Our operating expenses increased by $1,105,038 or 48.4% to $3,389,705 in 2022 compared to $2,284,667 in 2021. The operating expenses were comprised primarily of consulting fees, professional fees, and stock-based compensation. This change was due primarily to an increase in stock-based compensation of approximately $1.2 million.